About Neurex Corporation
Neurex was a late-stage biopharmaceutical company developing products for neurological diseases and pain management. Its strategy was to discover, develop and commercialize its products for acute care treatment in hospital settings, such as emergency rooms, intensive care units and pain clinics. It had Corlopam approved in the US for the treatment of severe hypertension in the hospital setting. It also had non-opiate pain therapeutic Ziconotide (SNX-111) for the treatment of chronic and acute pain. It was acquired by Elan in April 2008 for 700M.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Neurex Corporation
Detailed funding history for Neurex Corporation
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Neurex Corporation
Neurex Corporation has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Elan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufacturer of OTC products, prescription pharmaceuticals, nutritional products, and APIs
|
Locked | Locked | Locked |
Investor details for Neurex Corporation
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neurex Corporation
Investment portfolio details for Neurex Corporation
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neurex Corporation
Detailed financials for Neurex Corporation
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neurex Corporation Comparisons
Peer comparison for Neurex Corporation
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neurex Corporation
Detailed competitors of Neurex Corporation
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neurex Corporation
Complete news archive for Neurex Corporation
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neurex Corporation
Neurex Corporation was founded in 1994.
Neurex Corporation is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Neurex was a late-stage biopharmaceutical company developing products for neurological diseases and pain management. Its strategy was to discover, develop and commercialize its products for acute care treatment in hospital settings, such as emergency rooms, intensive care units and pain clinics. It had Corlopam approved in the US for the treatment of severe hypertension in the hospital setting. It also had non-opiate pain therapeutic Ziconotide (SNX-111) for the treatment of chronic and acute pain. It was acquired by Elan in April 2008 for 700M.
Neurex Corporation has 1 investor. Key investors include Elan.